• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright initiated coverage on Kinnate BioPharma with a new price target

    7/28/22 7:41:00 AM ET
    $KNTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNTE alert in real time by email
    H.C. Wainwright initiated coverage of Kinnate BioPharma with a rating of Buy and set a new price target of $33.00
    Get the next $KNTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KNTE

    DatePrice TargetRatingAnalyst
    11/17/2022$35.00 → $11.00Buy → Hold
    Stifel
    7/28/2022$33.00Buy
    H.C. Wainwright
    9/27/2021$46.00Buy
    Jefferies
    9/23/2021$32.00Buy
    Stifel
    7/13/2021Outperform
    William Blair
    More analyst ratings

    $KNTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kinnate BioPharma downgraded by Stifel with a new price target

      Stifel downgraded Kinnate BioPharma from Buy to Hold and set a new price target of $11.00 from $35.00 previously

      11/17/22 7:29:36 AM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Kinnate BioPharma with a new price target

      H.C. Wainwright initiated coverage of Kinnate BioPharma with a rating of Buy and set a new price target of $33.00

      7/28/22 7:41:00 AM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Kinnate Biopharma with a new price target

      Jefferies initiated coverage of Kinnate Biopharma with a rating of Buy and set a new price target of $46.00

      9/27/21 5:06:44 AM ET
      $KNTE
      Biotechnology: Pharmaceutical Preparations
      Health Care